This study aimed to analyse data from two different studies ( phase II and phase III ) regarding the safety and efficacy of treatment with alum formulated glutamic acid decarboxylase GAD65 ( GAD-alum ) at 30 months after administration to children and adolescents with type 1 diabetes .